Primary prevention with statins, consensus and risk tables;Prevención primaria con estatinas, consensos y tablas de riesgo

Atencion Primaria

Volumn 36, Issue 1, 2005, Pages 31-38

  Miguel Garcia F ^a,b,d   Garcia Ortiz A ^a,b   Montero Alonso, M J ^c  

^a Servicio de Programas de Salud y Prevención de la Dirección Técnica de Recursos Humanos y Gestión de Centros Gerencia de Servicios Sociales   (Spain)

^b Dirección General de Asistencia Sanitaria   (Spain)

^c Área de la Gerencia de Atención Primaria de Valladolid Este   (Spain)

^d Departamento de Salud Pública   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR RISK; HUMAN; HYPOLIPEMIA; ISCHEMIC HEART DISEASE; REVIEW;

EID: 21844456065     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1157/13075929     Document Type: Article

References (38)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97. Informe completo disponible en: www.nhlbi.nih.gov/guidelines/ cholesterol/
2. Grupo de Trabajo de Prevencion Cardiovascular del PAPPS. Actividades preventivas cardiovasculares en atención primaria. Aten Primaria. 2003;32 Supl 2:15-29.
3. Maiques Galán A, Villar Álvarez F. Tablas de riesgo cardiovascular y evidencias. En defensa de la tabla de Framingham calibrada [respuesta de los autores]. Aten Primaria. 2004;33:409-11.
4. Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronay and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58.
5. Katerndahl DA, Lawler WR. Variability in meta-analytic results concerning the value of cholesterol reduction in coronary heart disease: a meta-meta-analysis. Am J Epidemiol. 1999;149:429-41.
6. Cholesterol and statins. Bandolier [serie en Internet]. 2004 Abr, extra. Disponible en: www.ebandolier.com
7. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22.
8. Grupo de Trabajo de la Sociedad Española de Medicina Familiar y Comunitaria. Guía de prevencion cardiovascular en atención primaria. Disponible en: http://www.papps.org/guiacardio/cardiovascular.pdf
9. Wallsh J, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004;291: 2243-52.
10. Shepherd J, Baluw G, Murphy MB, Bollen E, Buckley BM, Cobbe S, et al. Pravastatin in elderly individuals at risk of vascular disease. Lancet. 2002;360:623-9.
11. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-8.
12. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288: 2998-3007.
13. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ. 2000;321:1-5.
14. Do statins have a role in primary prevention? Therapeutics Letter. 2003, n.° 48. Disponible en: www.ti.ubc.ca
15. Jackson PR, Wallis EJ, Haq IU, Ramsay E. Statins for primary prevention: at what coronary risk is safety assured? J Clin Pharmacol. 2001;52:439-46.
16. Cucherat M, Lievre M, Gueyffier F. Clinical benefits of cholesterol lowering treatments. Meta-analysis of randomized therapeutic trials. Presse Med. 2000;29:965-76.
17. Vrecer M, Turk S, Drinovec J, Mrhar A. Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomiced trials. Int J Clin Pharmacol Ther. 2003;41:567-77.
18. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Impact of Statin Trials. Circulation. 1998;97:946-52.
19. Ministerio de Sanidad y Consumo, Sociedad Española de Cardiología y Sociedad Española de Arterioesclerosis. Control de la colesterolemia en España, 2000 un instrumento para la prevención cardiovascular. Rev Esp Salud Pública. 2000;74;215-53.
20. Ministerio de Sanidad y Consumo. Plan Integral de Cardiopatía isquémica 2004-2007. Madrid: Ministerio de Sanidad y Consumo; 2003.
21. Third Joint Task Force of European and other Societies on cardiovascular disease prevention in clinical practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601-10.
22. Ramos R, Solanas P, Cordón F, Rohlfs I, Elosua R, Sala J, et al. Comparación de la funcion de Framingham original y la calibrada del REGICOR en la predicción del riesgo coronario poblacional. Med Clin (Barc). 2003;121:521-6.
23. Anderson KM, Wilson PW, Odel PM, Kannel WM. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:356-62.
24. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
25. Disponible en: www.fundacioninfosalud.org/cardio/cv_scalas.htm
26. Maiques A. Valoración del riesgo cardiovascular. ¿Qué tabla utilizar? Aten Primaria. 2003;32:586-9.
27. Marrugat J, D'Agostino R, Sullivan L, Elosua R, Wilson P, Ordovás J, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Heath. 2003;57:634-8.
28. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovas J, Cordon F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253-61.
29. Aranceta J, Pérez C, Foz M, Mantilla T, Serra L. Moreno B, et al, y Grupo Colaborativo para el estudio Dorica fase II. Tablas de evaluación del riesgo coronario adaptadas a la población española. Estudio DORICA. Med Clin (Barc). 2004;123:686-61.
30. Marrugat J. Acerca de la participación en los estudios epidemiológicos. Med Clin (Barc). 2000;114:115.
31. The Second Joint Task Force of European and other Societies on Coronary Prevention. Prevention of coronary heart disease in clinical practice. European Heart Journal. 1998;19: 1434-1503.
32. Maiques A, Antón F, Franch M, Albert X, Aleixandre E, Collado Á. Riesgo cardiovascular del SCORE comparado con el de Framingham. Consecuencias del cambio propuesto por las sociedades europeas. Med Clin (Barc). 2004;123:681-5.
33. Gómez MA, García L, Sánchez A, González LJ, Santos I, Ramos E, et al. Changes in use of antihipertensive medication in Spanish primare care during last five years. Comunicación presentada al Congreso Europeo de Hipertensión. París, 2004. Disponible en http://www.laalamedilla.org/Investigacion/co municaciones2004.htm
34. Ramos R, Marrugat J. Valoración del riesgo cardiovascular en la población. En: Del Río Ligori A, editor. Mannual de cardiología preventiva. Madrid: SMC; 2005.
35. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who have a myocardyal infarction: cross sectional and cohor studies. BMJ. 2003;324:939-13.
36. Lotufo PA, Gaziano M, Chae CU, Ajani UA, Moreno-John G, Buring JE, et al. Diabetes and all cause and coronary heart disease mortality among US male phisicians. Arch Intern Med. 2001;161:242-7.
37. Lee ChD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular events in diabetic and no diabetic aduts with or without history of miocardial infarction. Circulation 2004;109:855-60.
38. Comité Español Interdisciplinario para la Prevención Cardiovascular (CEIPC). Adaptación española de la Guía Europea de Prevención Cardiovascular. Aten Primaria. 2004; 34:427-32.